IP Library Granted Patent US 8,883,750
Granted Patent B2
US 8,883,750 · App. 13/655,252 · Granted Nov 11, 2014

Method of treating diabetes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,883,750
App. No.
13/655,252
Granted
Nov 11, 2014
Kind
B2
Abstract

Methods are provided for treating diabetes, lowering plasma level of HbA1c, glucose plasma levels, total cholesterol plasma level, and/or triglyceride plasma level while increasing HDL cholesterol levels and delaying onset of diabetic retinopathy in a diabetic, pre-diabetic, or non-diabetic mammal while minimizing undesirable side effects.

Claims (4)

1. A method of treating diabetes in a human patient in need thereof, comprising administering to the patient a therapeutically effective amount of ranolazine, as a racemic mixture or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an agent selected from the group consisting of sulfonylurea, meglitinide, biguanide, thazolidinedione, alpha glucosidase inhibitor and ACE inhibitor, wherein HbA1c level, as measured after 12 weeks of administration, is reduced in the patient and wherein the patient is not on insulin.

2. The method of claim 1 , wherein the biguanide is metformin.

3. The method of claim 1 , wherein the patient is non-insulin dependent.

4. The method of claim 1 , wherein the HbA1c level is reduced by at least 0.48 percentage point.

Assignments (3)
MERGER Recorded Jan 24, 2014
From: APEX MERGER SUB, INC.; CV THERAPEUTICS, INC.
To: GILEAD PALO ALTO, INC.
Reel/Frame 032036/0186 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2014
From: JERLING, MARKUS; WOLFF, ANDREW A.
To: CV THERAPEUTICS, INC.
Reel/Frame 032019/0769 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2013
From: GILEAD PALO ALTO, INC.
To: GILEAD SCIENCES, INC.
Reel/Frame 031864/0586 →